Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human Genome Sciences has reported positive interim quality-of-life results from a phase IIb clinical trial to evaluate the efficacy, safety of Albuferon in combination with ribavirin in patients with hepatitis C.
Subscribe to our email newsletter
The interim results demonstrate that all Albuferon treatment groups consistently performed favorably compared to the pegylated interferon alpha treatment group, based on patient-reported disability days and health-related quality of life.
“Health-related quality-of-life issues, including lost days of work and normal activity, pose a significant challenge for patients undergoing treatment for chronic hepatitis C,” said Stephen Pianko, associate professor of medicine, Monash University in Australia.
David Stump, executive vice president of drug development at Human Genome Sciences said that results in mental health suggested significantly less impairment of psychological well-being across the Albuferon treatment groups.
Albuferon is being developed by Human Genome Sciences and Novartis under a worldwide development and commercialization agreement entered into in June 2006.